Psychosomatic Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harris, K. F.
Right arrow Articles by Matthews, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harris, K. F.
Right arrow Articles by Matthews, K. A.
Related Collections
Right arrow Psychophysiology
Right arrow Stress and Coping
Right arrow Coronary Artery Disease
Psychosomatic Medicine 66:153-164 (2004)
© 2004 American Psychosomatic Society


REVIEW ARTICLES

Interactions Between Autonomic Nervous System Activity and Endothelial Function: A Model for the Development of Cardiovascular Disease

Kelly F. Harris, MS and Karen A. Matthews, PhD

From the Department of Psychology, University of Pittsburgh (K.F.H.), and the Departments of Psychiatry, Epidemiology, and Psychology, University of Pittsburgh School of Medicine, (K.A.M.), Pittsburgh, PA.

Address reprint requests to: Karen A. Matthews, PhD, Cardiovascular Behavioral Medicine, Department of Psychiatry, WPIC, 3811 O’Hara Street, Pittsburgh, PA 15213. E-mail: matthewska{at}umpc.edu

ABSTRACT

OBJECTIVES: Endothelial dysfunction is a new pathway in cardiovascular disease (CVD) development. Psychosocial factors have been little studied in relation to endothelial function, although they may interact via associations with the autonomic nervous system (ANS). The purpose of this review is to propose a model by which psychosocial factors are related to CVD development through interactions between the ANS and vascular endothelium.

METHODS: The literature supporting an interaction between the ANS and endothelium in healthy and disease states is reviewed. Potential mechanisms linking the two systems are explored as a pathway for CVD development.

RESULTS: Endothelial dysfunction and impaired cardiovascular ANS regulation are both markers for increased CVD risk. Sympathetic nerves and vascular endothelial cells share a functional antagonism in healthy states to maintain appropriate blood vessel tone. Alterations in sympathetic activity and endothelial cell function are both observed early in the development of CVD and may result from an inability to maintain the functional antagonism. Impairments in either ANS regulation or endothelial function may contribute to further disease development by evoking maladaptive changes in the opposing system.

CONCLUSIONS: Although interactions between cardiovascular ANS regulation and endothelial function are likely involved in CVD development, further research is needed to determine whether ANS and endothelium interactions are a plausible pathway linking psychosocial factors with increased CVD risk.

Key Words: endothelial function, • autonomic nervous system, • sympathetic nervous system, • pathophysiology, • cardiovascular disease, • psychosocial stress.

Abbreviations: CVD = cardiovascular disease;; ANS = autonomic nervous system;; SNS = sympathetic nervous system;; PSNS = parasympathetic nervous system;; NO = nitric oxide;; CAD = coronary artery disease;; FMD = flow-mediated dilation;; HRV = heart rate variability;; vWF = von Willebrand factor;; LDL = low-density lipoprotein;; NOS = nitric oxide synthase;; HPA = hypothalamic-pituitary-adrenal.

INTRODUCTION

Cardiovascular disease (CVD) development is a complicated process. Fortunately, new technologies are providing fresh insights on the mechanisms of CVD pathogenesis. Endothelial function is one new measure that is broadening our understanding of CVD development. Endothelial cells play an important role in maintaining the structural and functional integrity of the vasculature. Inability of the endothelial cells to stimulate vasodilation properly is referred to as endothelial dysfunction. Endothelial dysfunction is believed to be one of the earliest stages of atherosclerosis and can be observed in healthy people with risk factors for heart disease (1). Endothelial dysfunction is correlated with subclinical measures of CVD and is prospectively associated with an increased risk for clinical CVD events (2).

Interactions between autonomic nervous system (ANS) regulation and endothelial function may provide a testable model for exploring a novel mechanism relating psychosocial factors to CVD development (Figure 1). Studies on psychosocial stress and negative psychosocial traits demonstrate associations with heightened sympathetic nervous system (SNS) activity (3, 4). Recent studies have suggested that similar psychosocial factors may also be linked with suppressed parasympathetic nervous system (PSNS) activity (5). Heightened SNS activity and suppressed PSNS activity impair the ability of the ANS to regulate the cardiovascular system (6). Impaired ANS regulation may be linked with CVD development through impairments in endothelial function. The endothelium shares a functional antagonism with SNS efferents in maintaining blood vessel tone. Research on the interrelationship between these two systems is growing. Interactions between the SNS and endothelial function provide an exciting new pathway for exploring mechanisms linking psychosocial factors with CVD.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 1. Model of associations between psychosocial factors, autonomic nervous system regulation, and endothelial function.

 
The objectives of this review are to summarize our current understanding of the interrelationship between endothelial function and the ANS and to propose how this interrelationship may play a role in linking psychosocial factors with an increased risk for CVD. First, we review the vascular endothelium and how it functions. Then, we summarize the literature on endothelial function in relation to CVD and psychosocial factors. Next, we discuss a model relating endothelial function to ANS activity, including a summary of interactions in a healthy state. After that, we explore the question of whether abnormalities in one of these systems may lead to maladaptive changes in the other. Finally, we review pathways by which the functionality of the ANS and endothelium may be indirectly linked. We conclude with suggestions for ways to apply this model to future research in cardiovascular behavioral medicine.

Various methods for measuring endothelial function (7, 8) and ANS activity (9, 10) have been discussed in detail elsewhere. In this review, studies examining endothelial function in humans were selected for inclusion based on adherence to standard procedures. Included studies primarily focused on examining vasodilatory responses in either the coronary or brachial artery. Brachial artery responses were measured in response to flow-mediated dilation because this measure is closely correlated with coronary artery endothelial function (11). Coronary endothelial function was primarily measured in response to acetylcholine or sympathetic stimulation via the cold pressor task. Variations of standard methodology are noted in the text where appropriate.

WHAT IS THE VASCULAR ENDOTHELIUM?

The endothelium is a single layer of cells that line the blood vessel lumen. These cells regulate vascular tone by responding to signals in the blood to release either vasodilating or vasoconstricting factors. Endothelial function is usually measured by exposing blood vessels to an endothelium-dependent vasodilating stimulus and then measuring the extent of vasodilation in response to the stimulus. Greater vasodilation reflects better endothelial function.

The primary vasodilator released by the endothelium is nitric oxide (NO) (12). Other relaxing factors released by the endothelium include endothelium-derived hyperpolarizing factor, prostacyclin, C-type natriuretic factor, 5-hydroxytryptamine serotonin (5-HT), adenosine triphosphate (ATP), substance P, and acetylcholine (13, 14). Basal blood flow maintains a continual release of endothelium-derived relaxing factors, and an increase in blood flow increases the release of relaxing factors (15). Increased release of NO from the endothelium results from changes in the shear stress on the vascular wall (16).

The endothelium also releases contracting factors, such as endothelin-1, angiotensin II, thromboxane A2, prostaglandin H2, superoxide anions, and ATP (13, 14). Stimuli that initiate release of these endothelium-dependent vasoconstrictors include norepinephrine, thrombin, hypoxia, and stretch (13). Normally, endothelin levels in the plasma are very low, likely because it is primarily released abluminally (17). Endothelin causes concentration-dependent arterial contractions that increase in magnitude in the absence of a functional endothelium (18). Higher levels of endothelin have been reported in some disease states, such as hypertension, although the role endothelin plays in these states is unclear (17). NO can eliminate endothelin-induced arterial constriction and inhibit further release of endothelin from the endothelium (14, 18).

Endothelial cells throughout the body are heterogeneous in function and may operate under different influences depending on the vascular bed (19). This is important to remember when comparing results of functional studies conducted on different vascular beds. Different stimuli also use different pathways of signal transduction to promote the release of vasodilating substrates (20). These multiple pathways may help to explain stimulus-specific impairments in endothelium-dependent vasodilator function.

IS ENDOTHELIAL FUNCTION RELATED TO RISK FOR CARDIOVASCULAR DISEASE?

Endothelial function is important because of its role in CVD development. In addition to regulating vessel tone, endothelial cells help to prevent the build-up of lipids and platelets that initiate the atherosclerotic process. Additionally, endothelial dysfunction may contribute to ischemic or arrhythmic events by preventing needy cells, such as those in the heart, from receiving the blood supply and nutrients required for proper functioning.

The endothelium releases a variety of substrates that play an important role in the inhibition of atherogenesis. Both NO and prostacyclin inhibit platelet activation and aggregation, whereas the release of tissue plasminogen activator enhances fibrinolysis (21). Other anticoagulant factors, such as thrombomodulin, are presented on endothelial cell surfaces to prevent cellular adhesion to the vascular wall (21). All of these mechanisms help to prevent the build-up of atherosclerotic plaque along arterial walls.

Inflammation is widely thought to play a role in the cardiovascular disease process. Damage to the endothelium can enhance inflammatory responses through the presentation of chemoattractants that promote cellular adhesion and uptake of lipids and macrophages into the abluminal space (22). Damage to the endothelium also results in the release of growth factors, such as platelet-derived growth factor, which can promote connective tissue growth and enhance smooth muscle cell proliferation, resulting in vascular wall thickening (22, 23). Loss of atheroprotective influences and activation of thrombosis, inflammation, and vascular growth all emphasize the negative effect of endothelial dysfunction on vascular health.

Numerous studies have linked impairments in endothelial function to CVD. When exposed to an endothelium-dependent vasodilator, such as acetylcholine, normal coronary arteries dilate, whereas irregular or stenosed vessels constrict (24). A similar response pattern has been demonstrated in the coronary arteries of patients with coronary artery disease (CAD) in response to the cold pressor test (25, 26). Even smooth coronary arterial segments of patients with CAD may constrict when exposed to cold (26).

Deficits in endothelial function can be evidenced in people with risk factors for CVD even in the absence of overt CVD. Among angiography patients with smooth coronary arteries, coronary diameter change in response to acetylcholine is lower in those who are older, are hypertensive, are male, have high cholesterol, or have a family history of early CVD (27, 28). Antony et al. (29) examined coronary vasomotor responses to the cold pressor test in two groups of angiography patients without evident CVD: patients with recently diagnosed hypertension and patients without risk factors for CVD. They found that all vessels in patients without hypertension dilated on exposure to cold, whereas all vessels in patients with hypertension either showed no change or constricted on exposure to cold (29). This pattern has also been demonstrated in the carotid artery: whereas carotid arteries from patients with CAD constrict, arteries from high-risk patients without CAD demonstrate mixed responses, and arteries from average-risk controls dilate in response to the cold pressor task (30).

Zeiher et al. (31) examined coronary diameter change with different endothelium-dependent vasodilators among angiography patients with different stages of disease . Patients with normal arteries and low risk for CAD dilated in response to all endothelium-dependent stimuli, including acetylcholine, cold exposure, and increased blood flow. Patients with normal arteries and high cholesterol dilated in response to cold exposure and increased blood flow but constricted in response to acetylcholine. Normal coronary arteries of patients with CAD in other vessels dilated in response to increased blood flow, whereas cold exposure or acetylcholine resulted in vasoconstriction. Abnormal vessel segments in patients with CAD constricted during cold exposure or in response to acetylcholine and failed to dilate in response to increased blood flow. These findings suggest that a progressive impairment of endothelial function is evident with progressive stages of CAD (31).

Endothelial function can be measured in the brachial artery of healthy samples using ultrasonography. Brachial artery endothelial function correlates well with the presence of CAD (11, 32, 33). Impaired brachial vasodilation in response to increased blood flow is evident in patients with coronary heart disease and patients with greater carotid artery intima-media thickness (32, 34). Healthy people with CVD risk factors have impaired brachial endothelial function even in the absence of clinical CVD. Celermajer et al. (1) showed that flow-mediated dilation (FMD) of either the brachial or femoral artery is impaired in adult smokers, children with hypercholesterolemia, and patients with CAD. Additional risk factors, such as high blood pressure, family history of early CVD, older age, male gender, and a higher composite risk factor score, are related to impaired FMD among apparently healthy people (35).

Prospective studies of patients with CAD show that impaired endothelial function predicts subsequent cardiac events (2, 36–38) . Additionally, non-CAD angiography patients who have abnormal coronary responses to acetylcholine are at an increased risk for subsequent CVD events (36). Perticone et al. (39) also showed that among hypertensive patients without known CVD, smaller increases in forearm blood flow in response to acetylcholine, a marker of microvascular endothelial function, predict subsequent clinical cardiovascular events. There are currently no studies examining the predictive value of endothelial function in an initially healthy sample.

IS ENDOTHELIAL FUNCTION RELATED TO PSYCHOSOCIAL FACTORS?

Few studies have examined endothelial function in relation to psychosocial traits. Harris et al. (40) tested correlations between psychosocial risk factors for CVD and endothelial function among a sample of postmenopausal women. They reported that women with higher anxiety scores had less FMD than women with lower anxiety scores. Among women not using any hormone replacement, higher scores on Type A behavior, trait anger, and depression were also associated with less FMD, indicating poorer endothelial function (40). However, because no endothelium-independent vasodilator was used in this study, impairment in vasodilatory function at the level of the smooth muscle cannot be ruled out. A second study demonstrated that patients with current major depression also demonstrated impairments in FMD relative to nondepressed controls (41). These studies suggest that psychosocial risk factors for CVD are associated with impairments in endothelial function.

Stress reactivity protocols have been used as stimuli for measuring endothelial function. As mentioned, the cold pressor test produces coronary vasomotor responses similar to those observed after administration of acetylcholine and increases in blood flow (26). Other stress reactivity protocols have also contributed to abnormal vasomotor responses in the coronary artery. Mental arithmetic results in a similar pattern of differential responses in diseased and healthy coronary vessels, where healthy vessels dilate and diseased vessels constrict during stress (42). High levels of experienced anger reported during an anger recall interview were associated with coronary vasoconstriction in narrowed segments of patients with CAD (43). Mental stress induced by performing a public speaking task during cardiac catheterization resulted in coronary vasoconstriction in CAD and non-CAD patients alike (44). It is important to point out that endothelial function was not specifically tested in these studies of mental stress. Therefore, although these studies suggest that vascular changes during mental stress may be used to measure endothelial function, more specific studies on endothelial function responses to mental stress are needed.

Relationships between psychosocial stress and endothelial function have also been examined in healthy people using brachial artery ultrasonography. Healthy men who performed a speech stress task for 5 minutes had lower brachial FMD responses at 30 and 90 minutes after the task relative to FMD responses before the task (45). This finding suggests that brief exposure to mental stress may induce temporary declines in endothelial function that remain after other physiological concomitants of stress exposure, such as alterations in blood flow and pressure, have returned to normal.

The mechanisms responsible for the effects of psychological stress on the endothelium have not been completely elucidated. Possible explanations for the endothelium-dependent dilatory response to stress include activation of {alpha}2-adrenergic receptors on the endothelium resulting in release of NO or hemodynamic alterations leading to endothelium-dependent FMD. In one sample of patients undergoing diagnostic cardiac catheterization, ß-blockade with propanolol only slightly attenuated the vasodilating response to the cold pressor test (25). In another similar study, propanolol administration failed to alter the vasomotor response of coronary arteries to the cold pressor test (26). However, both studies reported significant increases in heart rate and blood pressure with exposure to cold (25, 26), suggesting that changes in blood flow hemodynamics may stimulate endothelium-dependent vasodilation during cold stress.

The relationship between stress-induced sympathetic stimulation and endothelial function suggests that psychosocial factors may be related to endothelial function via ANS pathways. Explanations of associations between psychosocial factors and CVD often involve differences in ANS regulation (46), especially heightened SNS activity (47). Psychosocial factors, such as stress, anger, and hostility, have been linked with greater sympathetic and lower parasympathetic activity, suggestive of imbalances in ANS regulation (3, 5). To assess potential connective links between psychosocial factors and endothelial function via ANS regulation, it is first important to understand the relationship between the ANS and the endothelium.

HOW DO THE ENDOTHELIUM AND THE AUTONOMIC NERVOUS SYSTEM INTERACT? A MODEL FOR CARDIOVASCULAR DISEASE RISK

Healthy State
In a normal state, the ANS and the endothelium work together to maintain vascular tone. There is a tonic balance between the release of vasodilating factors from the endothelium and vasoconstricting factors from sympathetic nerve terminals (Figure 2). The balance between these opposing forces acts on the vascular smooth muscle cells to maintain the appropriate vessel tone (48).



View larger version (61K):
[in this window]
[in a new window]
 
Figure 2. Normal interactions between the autonomic nervous system and endothelium in regulating smooth muscle tone.

 
The vascular smooth muscle cell layer lies between the ANS nerve terminals and the endothelial cells lining the blood vessel lumen. Activation of ß-adrenergic receptors on vascular smooth muscle cells contributes to vasodilation (49), whereas activation of {alpha}1-adrenergic, and to a lesser extent, {alpha}2-adrenergic receptors on smooth muscle cells contributes to smooth muscle cell contraction, resulting in vasoconstriction (49–51). Parasympathetic stimulation of muscarinic receptors on smooth muscle cells also results in contraction and therefore vasoconstriction (52). In contrast, release of vasodilating factors, such as NO, from the endothelium stimulates smooth muscle cell relaxation, resulting in vasodilation.

The ANS may directly influence the endothelium. Endothelial cells possess both {alpha}2-adrenoceptors and ß-adrenoceptors (49, 53). In the coronary and large conduit arteries, activation of endothelial {alpha}2-adrenergic receptors releases NO, resulting in vasodilation (20, 49, 54). This endothelium-dependent vasodilatory effect of {alpha}2-adrenergic receptor activation counteracts the vasoconstricting effect of {alpha}1-adrenergic receptor stimulation of the vascular smooth muscle (50, 53). The function of ß-adrenoceptors on the endothelium is unclear, although a possible role in endothelium-dependent NO-mediated vasorelaxation has been speculated (49). In addition to vasodilators, the SNS can stimulate the release of endothelium-derived contracting factors, such as endothelin (48, 55). Endothelial cells also possess receptors for the primary PSNS neurotransmitter, acetylcholine. Activation of these receptors produces endothelium-dependent relaxation of human coronary arteries (52).

Although endothelial cells in the microvasculature may receive ANS inputs, endothelial cells along the major conduit vessels do not receive direct neural innervation from the ANS (48). Therefore, the effects of neurotransmitters on endothelial function must be exerted by circulating levels or by diffusing through the smooth muscle cell layer without degradation. Some evidence suggests that ANS neurotransmitters are able to diffuse across the vascular smooth muscle cells to act on the endothelium (14). Animal studies show that alterations in endothelial function occur after ANS denervation (48). In isolated rat mesenteric vessels, vasomotor responses to electrical stimulation of perivascular nerves are similar to responses after perfusion of the lumen with norepinephrine (16), suggesting that ANS efferents can directly influence endothelial cells. In contrast, others suggest that endothelial cells respond to changes in smooth muscle tone after sympathetic stimuli and not direct neural stimulation. When the vasoconstriction after sympathetic stimulation is blocked, relaxing factors are not released from endothelium, despite the presence of SNS-derived substrates (56). This suggests that sympathetic nerves do not directly increase release of endothelium-derived relaxing factors. Instead, vasoconstriction resulting from the release of norepinephrine from sympathetic nerve terminals may stimulate the increases in endothelium-derived NO (56).

The endothelium may affect the extent to which the ANS regulates vascular tone. Basal release of NO attenuates sympathetic vasoconstriction (51). In the presence of arterial shear stress, the endothelium can further depress vasoconstrictive responses to sympathetic nerve norepinephrine release in rabbit carotid arteries, likely because of increased release of NO (57). The endothelium may also inhibit SNS activity by contributing to the metabolic breakdown of norepinephrine and by providing a physical barrier to prevent diffusion of the neurotransmitter into the bloodstream (56, 58) . NO released from the endothelium decreases the sensitivity of smooth muscle cells to the vasoconstrictor effects of the SNS and inhibits central and peripheral SNS activity (14, 18, 59) HREF="#R18-1021">. In contrast, NO may increase central and peripheral PSNS activity while enhancing sensitivity to PSNS sites of action (59). This suggests that NO released from endothelial cells may play a role in modulating the balance between the SNS and PSNS branches of the ANS. However, caution must be exercised when drawing conclusions about endothelial function based on measures of NO alone. NO is released by various other sites in the body, including the newly suggested neuronal NO, which may also be involved in ANS regulation (59).

Other endothelial substrates also influence ANS function. In rat mesenteric arteries, low levels of endothelin inhibit norepinephrine release from sympathetic nerve terminals, resulting in a slightly lower arterial pressure (60, 61). However, at higher levels, endothelin can increase the sensitivity of smooth muscle cells to norepinephrine, resulting in increases in arterial pressure (60, 61). Therefore, endothelin at normal levels may suppress SNS-induced vasoconstriction, whereas excess endothelin release may enhance vasoconstrictive responses to SNS stimulation. In support of this, endothelin can enhance norepinephrine-induced vasoconstriction in isolated human mammary arteries (18). However, caution must always be exercised when interpreting studies using animals or isolated vessel segments because the results may not carry through to intact human samples.

In general, the endothelium and ANS act in opposition to maintain the appropriate vessel tone. This tone is a reflection of local and systemic factors. To serve both purposes, the endothelium may be more responsive to local factors, whereas the ANS may be more responsible for integrating systemic factors (62). In this way, the endothelium and ANS work together to create an ideal balance between the needs of local tissues and those of other systems.

What Happens When Things Go Wrong?
Disease states or negative lifestyle characteristics may predispose susceptible people to impairments in ANS regulation or endothelial function. Although ANS dysregulation and endothelial dysfunction co-occur, it is difficult to determine the driving force behind the associations. Impairments in ANS regulation may contribute to abnormal changes in endothelial cells, resulting in endothelial dysfunction, or impairments in endothelial function may lead to maladaptive alterations in ANS regulation. Additionally, many other factors are related to both ANS and endothelial function. These third party factors may link alterations in ANS and endothelial function. It is important to identify which factors are responsible for alterations in ANS and endothelial function to understand better the role these factors play in the development of CVD.

What Are the Direct Links Between the Autonomic Nervous System and Endothelial Function?
Correlations Between Impairments in the Autonomic Nervous System and Endothelial Function
Evidence for potential correlations between ANS and endothelial function comes from disease states associated with impairments in both systems. In addition to CVD, diabetes, hypertension, and congestive heart failure are associated with abnormalities in ANS regulation of the cardiovascular system (63–65). All of these disease states are similarly associated with impairments in endothelial function (66–68). It is unclear whether the ANS and endothelial systems are negatively affecting one another, or whether both systems undergo dysregulation as a consequence of the disease process.

Some studies show correlations between impaired endothelial function and greater resting systolic blood pressure, diastolic blood pressure, and heart rate (30, 69), although these correlations are not consistent (30, 38, 69). Few studies have directly examined correlations between cardiovascular changes to stress and endothelial function. One study showed that impaired femoral artery FMD was related to greater systolic blood pressure reactivity to physical challenges in children (70). In another study, impaired brachial FMD correlated with greater increases in vascular resistance during mental stress in adults (69). This finding raises the possibility that cardiovascular reactivity may be a crude marker of endothelial function.

Indirect evidence suggests a potential association between heart rate variability (HRV) and endothelial function. Decreased HRV correlates with greater arterial stiffness among patients with diabetes (71). Endothelin levels correlate negatively with some measures of HRV among patients with congestive heart failure (72). Among patients with diabetes, lower HRV is associated with higher levels of von Willebrand factor (vWF), an indirect marker of endothelial function (73).

Can Impaired Autonomic Function Contribute to Endothelial Dysfunction?
Currently, the best evidence of alterations in endothelial function resulting from ANS-related mechanisms comes from experimental data. Exaggerated SNS activity may impair endothelial function and enhance endothelium-mediated atherogenic processes. Chronic stimulation of perivascular nerves in the rabbit ear artery contributes to structural changes in the endothelial cells along the arterial wall (74). Endothelial cells exposed to chronic stimulation by perivascular nerves express greater immunoreactivity (74). High levels of circulating catecholamines upregulate the interferon-{gamma}–induced expression of class II major histocompatibility complex (MHC) receptors in bovine cerebral capillary endothelial cells, indicating that catecholamines may contribute to the induction of macrophages into the abluminal space (75). Circulating catecholamines may also increase the uptake of low-density lipoproteins (LDLs) by endothelial cells (76).

Some of the best evidence for a negative effect of SNS activity on endothelial function comes from studies examining psychosocial stress in nonhuman primates. The psychosocial stress is induced by exposing monkeys to a novel social environment (ie, the test monkey is placed in a cage with several unfamiliar monkeys). This stimulus is a very potent stressor because the test monkey is forced to establish a new position along the dominance hierarchy through repeated aggressive interactions with other monkeys. Monkeys exposed to unstable social environments demonstrated coronary vasoconstriction to acetylcholine, indicating that endothelial function was impaired (77). After psychosocial stress, monkeys treated with saline demonstrated more endothelial cell death and replication than monkeys treated with ß-blockade (78). These results indicate that SNS activation may contribute to impaired endothelial function, possibly because of activation of ß-adrenergic receptors.

As noted, mental stress may be linked with reduced endothelial function. Studies in nonhuman primates suggest that ß-adrenergic receptor blockade may protect endothelial cells from the negative effect of heightened SNS activity. However, do the beneficial effects of ß-blockade occur in humans as well? Hypertensive men treated for 22 weeks with either the ß-adrenergic receptor blocker atenolol or the {alpha}-adrenergic receptor blocker doxazosin had lower levels of circulating vWF after treatment than before treatment (79). The men treated with atenolol also demonstrated declines in circulating endothelin (79). Treatment with the ß-blocker propanolol may also improve vWF antigen levels among patients with hyperthyroidism (80). Treatment with the ß-blocker carvedilol for 4 months improved brachial FMD among patients with CAD (81). Studies examining the effects of ß-adrenergic receptor blockers on resistance vessel endothelial function have generally failed to show a beneficial effect (82–84). However, different types of ß-adrenergic receptor blockers may influence resistance vessel endothelial function in different ways (85). These studies indicate that although the effects of ß-adrenergic receptor blockade on resistance vessels are unclear, ß-blockers may improve deficits in endothelial function among the larger conduit vessels.

Additionally, {alpha}-receptors may also be an important link between SNS activity and impaired endothelial function. Hijmering et al. (86) measured FMD in healthy people at rest and while undergoing sympathetic stimulation using lower body negative pressure. Sympathetic stimulation resulted in a significant reduction in FMD that was abolished in subjects who underwent {alpha}-receptor blockade before the SNS stimulus (86).

Can Endothelial Dysfunction Contribute to Impairments in the Autonomic Nervous System?
Impaired endothelial function may influence ANS activity through alterations in neurotransmitter release, reuptake, or receptor sensitivity. Removal of the endothelium increased the release of norepinephrine from sympathetic nerve terminals in rabbit carotid arteries (54). Alterations in neurotransmitter release from SNS nerve terminals may result from decreased NO release. Among 15 healthy men, reduced NO release caused by the inhibition of nitric oxide synthase (NOS), a catalyst for NO production, enhanced muscle sympathetic nerve activity, suggesting that basal release of NO inhibits SNS activity (87).

Inability of the endothelium to counteract sympathetic vasoconstricting factors may contribute to mental stress-induced ischemia (88). Inasmuch as impaired endothelial function contributes to ischemic episodes, it may also exert an influence on neuronal reuptake of norepinephrine. Sobey et al. (89) demonstrated that ischemia followed by reperfusion of rabbit thoracic aorta enhanced sensitivity to norepinephrine because of an impaired ability of sympathetic neurons to reuptake norepinephrine. The direct effect of endothelial dysfunction on neuronal reuptake requires further investigation.

Endothelial dysfunction enhances the contractile effect of catecholamines. Sympathetic nerve stimulation contributed to greater carotid artery constriction in rabbits fed a high cholesterol diet than in rabbits fed a normal diet, and removal of the endothelium eliminated this difference (90). This result suggests that enhanced constriction to sympathetic stimulation in high-cholesterol rabbits is caused by endothelial dysfunction. Indeed, removal of the endothelium from rabbit carotid arteries increased norepinephrine-induced smooth muscle cell contraction (54). Similar findings have been reported in humans. Angiography patients with coronary endothelial dysfunction demonstrate enhanced coronary vasoconstriction to sympathetic stimulation with the {alpha}-adrenergic agonist phenylephrine (27). This enhanced vasoconstriction occurs in the absence of any changes in heart rate, blood pressure, or blood flow (27). Therefore, impaired endothelial function increases the contractile effects of SNS stimulation and may increase neurotransmitter release while decreasing reuptake.

Only one study has prospectively examined the effect of endothelial dysfunction on ANS activity in humans. In recently diagnosed patients with diabetes followed for 3 years, higher vWF levels predicted a subgroup of patients with diabetes who subsequently developed deficits in lower limb nerve conduction velocity (91). This finding suggests that endothelial dysfunction may predispose patients with diabetes to impairments in peripheral neural conduction. Because none of the patients in this sample developed deficits in ANS function, further follow-up is expected to clarify whether elevated vWF will similarly predict future autonomic neuropathy (91).

What Are the Indirect Links Between the Autonomic Nervous System and Endothelial Function?
In addition to the direct influence of ANS regulation and endothelial function on one another, other factors may indirectly link deficits in these two systems (Figure 3). Each of these third party factors shows some evidence of being linked with both ANS regulation and endothelial function. It is currently unclear whether these factors may also mediate associations between impairments in the ANS and endothelium.



View larger version (16K):
[in this window]
[in a new window]
 
Figure 3. Indirect associations between autonomic nervous system regulation and endothelial function.

 
Reproductive Axis
Women and men differ in relation to ANS regulation and endothelial function (35, 92–95). Gender differences in vascular regulation may result from differences in sex hormones. Estrogen stimulates the release of NO from the endothelium by increasing NOS and enhancing NOS activity (93, 96). Estrogen is also associated with lower levels of endothelin and decreased sensitivity to the vasoconstrictive effects of the peptide (93). Premenopausal women and postmenopausal women using hormone replacement have greater brachial artery FMD than postmenopausal women not using hormone replacement therapy (97, 98).

Autonomic regulation also differs between premenopausal and postmenopausal women (92). Some suggest that estrogen may influence ANS function by upregulating PSNS activity and downregulating SNS activity (92). However, studies examining the influence of estrogens on cardiovascular responses to stress have produced mixed results, with some showing a protective effect (99) and some showing no effect of estrogen (100).

Most studies show a positive influence of estrogen on the vascular endothelium, and some suggest that estrogen helps to regulate ANS function. Sex hormones are important modulators of vascular activity and may provide one link between alterations in ANS and endothelial function. The role of sex hormones as a communicative link between the ANS and endothelium has not yet been explored.

Oxidative Stress
Evidence exists for a negative influence of oxidative stress on both ANS and endothelial function. Oxidative stress may impair endothelial function by two mechanisms: free radicals, such as superoxide anion, and lipid peroxidation (101). Oxygen radicals can inhibit NO by combining with it to form peroxynitrite (101). Oxidized LDL inactivates NO and NOS, increases the release of oxidized anions from the endothelium, and is directly cytotoxic to endothelial cells (101, 102). Oxidative stress promotes the release of endothelin from the endothelium and can enhance endothelin activity (103). Exposure to oxidants causes morphological changes in endothelial cells, and these changes decrease the ability of the endothelium to provide a barrier between the blood and subendothelial matrix (104). Oxidative stress promotes leukocyte adhesion to endothelial cells (104). The combination of increased leukocyte adhesion and increased permeability of the endothelial layer implicates oxidative stress as an important event in the initiation of the atherosclerotic process (104). Indeed, in comparing asymptomatic patients with moderate carotid artery stenosis to healthy controls, the patients had higher levels of oxidized LDL, greater evidence of oxidative stress, and more circulating endothelin than controls (105).

Oxidative stress also contributes to impairments in ANS function. Oxidation induces neuronal cell death, including apoptosis of SNS neurons (106). Peroxynitrite, formed from the interaction of superoxide anion with NO, is a principal oxidizing agent of the ANS (107). Administration of the antioxidant vitamin E to patients with type II diabetes mellitus reduced circulating epinephrine and norepinephrine levels and improved HRV (108). Overall, changes in ANS function with vitamin E supplementation reflect an upregulation of the PSNS with a concomitant downregulation of the SNS, possibly by attenuating the negative effect of oxidative stress on ANS function (108).

Platelet Activation
Impaired ANS regulation is associated with greater platelet activation, contributing to enhanced aggregation and adhesion to vessel walls (109). In contrast, endothelial cells may act in opposition by inhibiting platelet activation, adhesion, and aggregation (110). Enhanced SNS activity may influence the interplay between the endothelium and circulating platelets, enabling platelet aggregation to commence at lower than normal levels of shear stress (111). Platelet activation can also negatively affect endothelial cell function (110, 112). Heightened SNS activity may therefore contribute to deficits in endothelial function because of enhanced platelet activation.

Renin-Angiotensin System
The connection between ANS regulation and the renin-angiotensin system is evident in healthy people and patients with CAD (113, 114) . Angiotensin II is a powerful vasoconstrictor synthesized by angiotensin-converting enzyme and may contribute to activation of central SNS processes and suppression of PSNS activity (115, 116) HREF="#R116-1021">. The endothelium may play a role in regulating the release of renin from the kidney, either directly or indirectly (117). The renin-angiotensin system also influences endothelial function (117). Therefore, the renin-angiotensin system may be another communicative pathway linking changes in the ANS and endothelium with adaptations in the other system.

Hypothalamic-Pituitary-Adrenal Axis
Sympathetic nervous system activity may play a role in activating the hypothalamic-pituitary-adrenal (HPA) axis (4). In contrast, glucocorticoids may suppress sympathetic activity (118). The complex relationship between ANS and HPA axis function, especially in regard to blood pressure regulation, may be better understood if the influence of another important blood pressure regulator, the endothelium, is also considered. However, few studies have examined the relationship between the HPA axis and endothelial function. Human endothelial cells possess adrenocorticotrophic hormone (ACTH) receptors, suggesting that interactions between these two systems do occur (119). Glucocorticoids such as cortisol can reduce adhesion of inflammatory molecules to endothelial cells, suggesting enhancement of endothelial function (120).

Insulin Resistance
Insulin resistance and SNS activity are correlated. Insulin resistance is associated with impairments in HRV and may contribute to enhanced SNS activity (65). SNS activity may similarly increase insulin resistance (121). Insulin produces vasodilatory responses that are at least partially endothelium-dependent and may help to protect endothelial function (122). Indeed, people with insulin resistance have poorer endothelial function than those without insulin resistance (66). Some have hypothesized that endothelial dysfunction is the primary cause of insulin resistance and accounts for associations between insulin resistance and other risk factors for CVD, including SNS overactivity (123, 124).

Aging
Autonomic nervous system nerves and endothelial cells both retain a great deal of plasticity even into adulthood (13). However, neither of these systems escapes eventual aging-related alterations. There is a progressive decline in brachial FMD with aging (125). Declines in NO, as measured by the metabolic by-product nitrate in the blood, and increases in endothelin are apparent in older people (126, 127). The decline in endothelial function with age is stimulus-dependent in that brachial vasodilator responses to the cold pressor test, a sympathetic stimulus, are blunted before brachial vasodilator responses to increased blood flow (94). Similar to the decline in endothelial function, ANS activity appears to be altered with aging, primarily reflecting enhanced SNS and suppressed PSNS activity (95, 127). Therefore, increased SNS-induced vasoconstrictive forces may overpower the declining endothelium-dependent vasodilatory forces with age.

DIRECTIONS FOR FUTURE RESEARCH

Interactions between ANS regulation and endothelial function are evident in healthy and diseased states. For this reason, studies exploring vascular reactivity need to consider both the ANS and endothelium in interpreting physiological responses to physical and psychosocial stress. Currently, much is unknown about the effect of alterations in one of these systems on the other. Evidence suggests that abnormalities in either ANS or endothelial function may negatively affect the function of the other system. However, this hypothesis has not been directly tested in humans. Future research should focus on uncovering both the effect of ANS dysregulation on endothelial function and the effect of endothelial dysfunction on ANS regulation.

Exploring the relationship between ANS and endothelial function provides a testable model for examining processes involved in CVD development. ANS regulation is related to CVD survival and predicts CVD incidence in healthy samples. Endothelial dysfunction is one of the earliest phases of atherosclerosis, and endothelial function can be measured noninvasively in healthy people before the onset of disease. For these reasons, examining endothelial function is useful for determining factors that influence the early development of CVD. Therefore, examining associations between the ANS and vascular endothelium may provide insight on the nature of CVD development and progression. However, many questions remain regarding interactions between ANS and endothelial function as a pathway of CVD development. First, can endothelial dysfunction predict CVD among an initially healthy sample? Are common measures of ANS regulation, such as pre-ejection period, muscle sympathetic nerve activity, and HRV, correlated with endothelial function? Do other third party factors associated with CVD risk mediate associations between ANS and endothelial dysfunction? Future research should address these questions to gain a better understanding of the role ANS and endothelial cell interactions play in the development of CVD.

As mentioned, interactions between ANS regulation and endothelial function may provide a testable model for exploring a novel mechanism relating psychosocial factors to CVD development (Figure 1). Psychosocial factors have been rarely studied in relation to endothelial function, providing a wide-open arena for research on this new pathway of disease development. Psychosocial factors are highly associated with measures of cardiovascular ANS regulation (4). Psychosocial stress and negative psychosocial traits may therefore predispose some people to patterns of ANS regulation that are detrimental to endothelial function. In this way, psychosocial risk factors for CVD may play a role in the disease process through the negative effect of ANS regulation on the endothelium. This hypothesis remains to be tested.

CONCLUSIONS

In summary, alterations in cardiovascular ANS regulation and endothelial function are highly implicated in the development of CVD. In normal arteries, the ANS and endothelium share a functional antagonism that maintains vascular tone. However, alterations in the balance between these two systems may lead to detrimental effects on the cardiovascular system. Overactivation of the ANS may directly impair endothelial function. Similarly, endothelial dysfunction may contribute to abnormalities in ANS regulation through alterations in neurotransmitter release, reuptake, or receptor sensitivity. Other factors, including sex hormones, oxidative stress, and many others, may also partially explain the co-occurrence of abnormalities in ANS regulation and endothelial function. Associations between impairments in ANS regulation and endothelial function provide a mechanistic link by which psychosocial factors may be related to the development of CVD.

Although there is much evidence linking the ANS and endothelium in healthy and diseased states, there are many questions remaining about the physiological processes involved in these links. Gaining a better understanding of this physiological relationship will provide new and exciting opportunities for determining the role of psychosocial processes in CVD development. Currently, there is much conflict within the literature on psychosocial factors and CVD. Further understanding the physiological pathways of psychosocial factors in disease can help bring clarity to this perplexing puzzle.

ACKNOWLEDGMENTS

Funding for this research was supported by the Pittsburgh Mind-Body Center Research Training Program HL07560.

Received for publication June 10, 2003.

REFERENCES

  1. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–5.[CrossRef][Medline]
  2. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899–906.[Abstract/Free Full Text]
  3. Burns JW, Friedman R, Katkin ES. Anger expression, hostility, anxiety, and patterns of cardiac reactivity to stress. Behav Med 1992; 18: 71–8.[Medline]
  4. Cacioppo JT, Malarkey WB, Kiecolt-Glaser JK, Uchino BN, Sgoutas-Emch SA, Sheridan JF, Berntson GG, Glaser R. Heterogeneity in neuroendocrine and immune responses to brief psychological stressors as a function of autonomic cardiac activation. Psychosom Med 1995; 57: 154–64.[Abstract/Free Full Text]
  5. Lucini D, Norbiato G, Clerici M, Pagani M. Hemodynamic and autonomic adjustments to real life stress conditions in humans. Hypertension 2002; 39: 184–8.[Abstract/Free Full Text]
  6. Dekker JM, Crow RS, Folsom AR, Hannan PJ, Liao D, Swenne CA, Schouten EG. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC Study. Atherosclerosis Risk In Communities. Circulation 2000; 102: 1239–44.[Abstract/Free Full Text]
  7. Raitakari OT, Celermajer DS. Testing for endothelial dysfunction. Ann Med 2000; 32: 293–304.[Medline]
  8. Vanhoutte PM. How to assess endothelial function in human blood vessels. J Hypertens 1999; 17: 1047–58.[CrossRef][Medline]
  9. Eckberg DL. Physiological basis for human autonomic rhythms. Ann Med 2000; 32: 341–9.[Medline]
  10. Venables PH. Autonomic activity. Ann N Y Acad Sci 1991; 620: 191–207.[Medline]
  11. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235–41.[Abstract]
  12. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524–6.[CrossRef][Medline]
  13. Burnstock G. Determinants of signal transmission in healthy and diseased autonomic neuromuscular junctions. Diabet Med 1993; 10: 64S–9S.
  14. Shepherd JT. Interactions of neurotransmitters and endothelial cells in determining vascular tone. Adv Exp Med Biol 1995; 381: 1–13.[Medline]
  15. Bassenge E, Munzel T. Consideration of conduit and resistance vessels in regulation of blood flow. Am J Cardiol 1988; 62: 40E–4E.[CrossRef][Medline]
  16. Boric MP, Figueroa XF, Donoso MV, Paredes A, Poblete I, Huidobro-Toro JP. Rise in endothelium-derived NO after stimulation of rat perivascular sympathetic mesenteric nerves. Am J Physiol 1999; 277: H1027–35.
  17. Luscher TF, Wenzel RR, Noll G. Local regulation of the coronary circulation in health and disease: role of nitric oxide and endothelin. Eur Heart J 1995; 16 (suppl): C51–8.
  18. Luscher TF, Yang Z, Tschudi M, von Segesser L, Stulz P, Boulanger C, Siebenmann R, Turina M, Buhler FR. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res 1990; 66: 1088–94.[Abstract/Free Full Text]
  19. Stevens T, Rosenberg R, Aird W, Quertermous T, Johnson FL, Garcia JG, Hebbel RP, Tuder RM, Garfinkel S. NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am J Physiol 2001; 281: C1422–33.
  20. Richard V, Tanner FC, Tschudi M, Luscher TF. Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries. Am J Physiol 1990; 259: H1433–9.
  21. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996; 47: 315–31.[CrossRef][Medline]
  22. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801–9.[CrossRef][Medline]
  23. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20: II-3–10.
  24. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046–51.[Abstract]
  25. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988; 77: 43–52.[Abstract/Free Full Text]
  26. Zeiher AM, Drexler H, Wollschlaeger H, Saurbier B, Just H. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol 1989; 14: 1181–90.[Abstract]
  27. Treasure CB, Manoukian SV, Klein JL, Vita JA, Nabel EG, Renwick GH, Selwyn AP, Alexander RW, Ganz P. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res 1992; 71: 776–81.[Abstract/Free Full Text]
  28. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491–7.[Abstract/Free Full Text]
  29. Antony I, Aptecar E, Lerebours G, Nitenberg A. Coronary artery constriction caused by the cold pressor test in human hypertension. Hypertension 1994; 24: 212–9.[Abstract/Free Full Text]
  30. Rubenfire M, Rajagopalan S, Mosca L. Carotid artery vasoreactivity in response to sympathetic stress correlates with coronary disease risk and is independent of wall thickness. J Am Coll Cardiol 2000; 36: 2192–7.[Abstract/Free Full Text]
  31. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391–401.[Abstract/Free Full Text]
  32. Enderle MD, Schroeder S, Ossen R, Meisner C, Baumbach A, Haering HU, Karsch KR, Pfohl M. Comparison of peripheral endothelial dysfunction and intimal media thickness in patients with suspected coronary artery disease. Heart 1998; 80: 349–54.[Abstract/Free Full Text]
  33. Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D, Bauer P, Weidinger F. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111–8.[CrossRef][Medline]
  34. Zhang X, Zhao SP, Li XP, Gao M, Zhou QC. Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease. Atherosclerosis 2000; 149: 19–24.[CrossRef][Medline]
  35. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468–74.[Abstract]
  36. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653–8.[Abstract/Free Full Text]
  37. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948–54.[Abstract/Free Full Text]
  38. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573–9.[Abstract/Free Full Text]
  39. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191–6.[Abstract/Free Full Text]
  40. Harris KF, Matthews KA, Sutton-Tyrrell K, Kuller LH. Associations between psychological traits and endothelial function in postmenopausal women. Psychosom Med 2003; 65: 402–9.[Abstract/Free Full Text]
  41. Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol 2001; 88: 196–8.[CrossRef][Medline]
  42. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1991; 325: 1551–6.[Abstract]
  43. Boltwood MD, Taylor CB, Burke MB, Grogin H, Giacomini J. Anger report predicts coronary artery vasomotor response to mental stress in atherosclerotic segments. Am J Cardiol 1993; 72: 1361–5.[CrossRef][Medline]
  44. Lacy CR, Contrada RJ, Robbins ML, Tannenbaum AK, Moreyra AE, Chelton S, Kostis JB. Coronary vasoconstriction induced by mental stress (simulated public speaking). Am J Cardiol 1995; 75: 503–5.[CrossRef][Medline]
  45. Ghiadoni L, Donald AE, Cropley M, Mullen MJ, Oakley G, Taylor M, O’Connor G, Betteridge J, Klein N, Steptoe A, Deanfield JE. Mental stress induces transient endothelial dysfunction in humans. Circulation 2000; 102: 2473–8.[Abstract/Free Full Text]
  46. Maliphant R, Hume F, Furnham A. Autonomic nervous system (ANS) activity, personality characteristics and disruptive behaviour in girls. J Child Psychol Psychiatry 1990; 31: 619–28.[Medline]
  47. Williams RB Jr, Suarez EC, Kuhn CM, Zimmerman EA, Schanberg SM. Biobehavioral basis of coronary-prone behavior in middle-aged men, part I: evidence for chronic SNS activation in type As. Psychosom Med 1991; 53: 517–27.[Abstract/Free Full Text]
  48. Burnstock G. Local mechanisms of blood flow control by perivascular nerves and endothelium. J Hypertens Suppl 1990; 8: S95–106.[CrossRef][Medline]
  49. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001; 53: 319–56.[Abstract/Free Full Text]
  50. Cohen RA, Zitnay KM, Weisbrod RM, Tesfamariam B. Influence of the endothelium on tone and the response of isolated pig coronary artery to norepinephrine. J Pharmacol Exp Ther 1988; 244: 550–5.[Abstract/Free Full Text]
  51. Vanhoutte PM, Miller VM. Alpha 2-adrenoceptors and endothelium-derived relaxing factor. Am J Med 1989; 87: 1S–5S.[Medline]
  52. van Zwieten PA, Hendriks MG, Pfaffendorf M, Bruning TA, Chang PC. The parasympathetic system and its muscarinic receptors in hypertensive disease. J Hypertens 1995; 13: 1079–90.[CrossRef][Medline]
  53. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 1983; 305: 627–30.[CrossRef][Medline]
  54. Tesfamariam B, Weisbrod RM, Cohen RA. Cyclic GMP modulators on vascular adrenergic neurotransmission. J Vasc Res 1992; 29: 396–404.[Medline]
  55. Bacic F, Uematsu S, McCarron RM, Spatz M. Secretion of immunoreactive endothelin-1 by capillary and microvascular endothelium of human brain. Neurochem Res 1992; 17: 699–702.[CrossRef][Medline]
  56. Tesfamariam B, Weisbrod RM, Cohen RA. Endothelium inhibits responses of rabbit carotid artery to adrenergic nerve stimulation. Am J Physiol 1987; 253: H792–8.
  57. Tesfamariam B, Cohen RA. Inhibition of adrenergic vasoconstriction by endothelial cell shear stress. Circ Res 1988; 63: 720–5.[Abstract/Free Full Text]
  58. Cohen RA, Weisbrod RM. Endothelium inhibits norepinephrine release from adrenergic nerves of rabbit carotid artery. Am J Physiol 1988; 254: H871–8.
  59. Chowdhary S, Townend JN. Nitric oxide and hypertension: not just an endothelium derived relaxing factor! J Hum Hypertens 2001; 15: 219–27.[CrossRef][Medline]
  60. Nakamaru M, Tabuchi Y, Rakugi H, Nagano M, Ogihara T. Actions of endothelin on adrenergic neuroeffector junction. J Hypertens Suppl 1989; 7: S132–3.[Medline]
  61. Tabuchi Y, Nakamaru M, Rakugi H, Nagano M, Higashimori K, Mikami H, Ogihara T. Effects of endothelin on neuroeffector junction in mesenteric arteries of hypertensive rats. Hypertension 1990; 15: 739–43.[Abstract/Free Full Text]
  62. Burnstock G. Integration of factors controlling vascular tone: overview. Anesthesiology 1993; 79: 1368–80.[Medline]
  63. Grassi G, Seravalle G, Bertinieri G, Turri C, Stella ML, Scopelliti F, Mancia G. Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Clin Sci 2001; 101: 141–6.[Medline]
  64. Liao D, Cai J, Brancati FL, Folsom A, Barnes RW, Tyroler HA, Heiss G. Association of vagal tone with serum insulin, glucose, and diabetes mellitus—the ARIC Study. Diabetes Res Clin Pract 1995; 30: 211–21.[CrossRef][Medline]
  65. Pikkujamsa SM, Huikuri HV, Airaksinen KE, Rantala AO, Kauma H, Lilja M, Savolainen MJ, Kesaniemi YA. Heart rate variability and baroreflex sensitivity in hypertensive subjects with and without metabolic features of insulin resistance syndrome. Am J Hypertens 1998; 11: 523–31.[CrossRef][Medline]
  66. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780–4.[Abstract/Free Full Text]
  67. Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996; 93: 210–4.[Abstract/Free Full Text]
  68. Li J, Zhao SP, Li XP, Zhuo QC, Gao M, Lu SK. Non-invasive detection of endothelial dysfunction in patients with essential hypertension. Int J Cardiol 1997; 61: 165–9.[CrossRef][Medline]
  69. Sherwood A, Johnson K, Blumenthal JA, Hinderliter AL. Endothelial function and hemodynamic responses during mental stress. Psychosom Med 1999; 61: 365–70.[Abstract/Free Full Text]
  70. Treiber F, Papavassiliou D, Gutin B, Malpass D, Yi W, Islam S, Davis H, Strong W. Determinants of endothelium-dependent femoral artery vasodilation in youth. Psychosom Med 1997; 59: 376–81.[Abstract/Free Full Text]
  71. Jensen-Urstad K, Reichard P, Jensen-Urstad M. Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. J Intern Med 1999; 245: 57–61.[CrossRef][Medline]
  72. Aronson D, Mittleman MA, Burger AJ. Role of endothelin in modulation of heart rate variability in patients with decompensated heart failure. Pacing Clin Electrophysiol 2001; 24: 1607–15.[CrossRef][Medline]
  73. Aso Y, Fujiwara Y, Tayama K, Inukai T, Takemura Y. Elevation of von Willebrand factor in plasma in diabetic patients with neuropathic foot ulceration. Diabet Med 2002; 19: 19–26.[CrossRef][Medline]
  74. Loesch A, Maynard KI, Burnstock G. Calcitonin gene-related peptide- and neuropeptide Y-like immunoreactivity in endothelial cells after long-term stimulation of perivascular nerves. Neuroscience 1992; 48: 723–6.[CrossRef][Medline]
  75. Coutinho GC, Durieu-Trautmann O, Strosberg AD, Couraud PO. Catecholamines stimulate the IFN-gamma-induced class II MHC expression on bovine brain capillary endothelial cells. J Immunol 1991; 147: 2525–9.[Abstract/Free Full Text]
  76. Born GV. Recent evidence for the involvement of catecholamines and of macrophages in atherosclerotic processes. Ann Med 1991; 23: 569–72.[Medline]
  77. Williams JK, Vita JA, Manuck SB, Selwyn AP, Kaplan JR. Psychosocial factors impair vascular responses of coronary arteries. Circulation 1991; 84: 2146–53.[Abstract/Free Full Text]
  78. Strawn WB, Bondjers G, Kaplan JR, Manuck SB, Schwenke DC, Hansson GK, Shively CA, Clarkson TB. Endothelial dysfunction in response to psychosocial stress in monkeys. Circ Res 1991; 68: 1270–9.[Abstract/Free Full Text]
  79. Seljeflot I, Arnesen H, Andersen P, Aspelin T, Kierulf P. Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. J Cardiovasc Pharmacol 1999; 34: 584–8.[CrossRef][Medline]
  80. Burggraaf J, Lalezari S, Emeis JJ, Vischer UM, de Meyer PH, Pijl H, Cohen AF. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid 2001; 11: 153–60.[CrossRef][Medline]
  81. Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J 2000; 140: 753–9.[CrossRef][Medline]
  82. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G, Oshima T. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol 2000; 35: 284–91.[Abstract/Free Full Text]
  83. Schiffrin EL. Vascular remodeling and endothelial function in hypertensive patients: effects of antihypertensive therapy. Scand Cardiovasc J Suppl 1998; 47: 15–21.[Medline]
  84. Schiffrin EL, Deng LY. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995; 25: 699–703.[Abstract/Free Full Text]
  85. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104: 511–4.[Abstract/Free Full Text]
  86. Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol 2002; 39: 683–8.[Abstract/Free Full Text]
  87. Owlya R, Vollenweider L, Trueb L, Sartori C, Lepori M, Nicod P, Scherrer U. Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation 1997; 96: 3897–903.[Abstract/Free Full Text]
  88. Yeung AC, Ganz P, Selwyn AP. Interactions between mental stress and coronary endothelial dysfunction. Homeostasis 1993; 34: 244–51.
  89. Sobey CG, Sozzi V, Woodman OL. Ischaemia/reperfusion enhances phenylephrine-induced contraction of rabbit aorta due to impairment of neuronal uptake. J Cardiovasc Pharmacol 1994; 23: 562–8.[Medline]
  90. Tesfamariam B, Weisbrod RM, Cohen RA. Augmented adrenergic contractions of carotid arteries from cholesterol-fed rabbits due to endothelial cell dysfunction. J Cardiovasc Pharmacol 1989; 13: 820–5.[Medline]
  91. Plater ME, Ford I, Dent MT, Preston FE, Ward JD. Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function. Diabetologia 1996; 39: 336–43.[Medline]
  92. Du XJ, Riemersma RA, Dart AM. Cardiovascular protection by oestrogen is partly mediated through modulation of autonomic nervous function. Cardiovasc Res 1995; 30: 161–5.[CrossRef][Medline]
  93. Schwertz DW, Penckofer S. Sex differences and the effects of sex hormones on hemostasis and vascular reactivity. Heart Lung 2001; 30: 401–26.[CrossRef][Medline]
  94. Corretti MC, Plotnick GD, Vogel RA. The effects of age and gender on brachial artery endothelium-dependent vasoactivity are stimulus-dependent. Clin Cardiol 1995; 18: 471–6.[Medline]
  95. Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol 1998; 31: 593–601.[Abstract/Free Full Text]
  96. Yang S, Bae L, Zhang L. Estrogen increases eNOS and NOx release in human coronary artery endothelium. J Cardiovasc Pharmacol 2000; 36: 242–7.[CrossRef][Medline]
  97. Bush DE, Jones CE, Bass KM, Walters GK, Bruza JM, Ouyang P. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med 1998; 104: 552–8.[CrossRef][Medline]
  98. McCrohon JA, Adams MR, McCredie RJ, Robinson J, Pike A, Abbey M, Keech AC, Celermajer DS. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin Endocrinol (Oxf) 1996; 45: 435–41.[CrossRef][Medline]
  99. Komesaroff PA, Esler MD, Sudhir K. Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. J Clin Endocrinol Metab 1999; 84: 606–10.[Abstract/Free Full Text]
  100. Matthews KA, Flory JD, Owens JF, Harris KF, Berga SL. Influence of estrogen replacement therapy on cardiovascular responses to stress of healthy postmenopausal women. Psychophysiology 2001; 38: 391–8.[CrossRef][Medline]
  101. Tomasian D, Keaney JF, Vita JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovasc Res 2000; 47: 426–35.[Free Full Text]
  102. Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA 1997; 278: 1682–6.[Abstract/Free Full Text]
  103. Kahler J, Mendel S, Weckmuller J, Orzechowski HD, Mittmann C, Koster R, Paul M, Meinertz T, Munzel T. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol 2000; 32: 1429–37.[CrossRef][Medline]
  104. Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol 2001; 280: C719–41.
  105. Signorelli SS, Neri S, Di Pino L, Costa MP, Pennisi G, Digrandi D, Ierna D. Oxidative stress and endothelial damage in patients with asymptomatic carotid atherosclerosis. Clin Exp Med 2001; 1: 9–12.[CrossRef][Medline]
  106. Park DS, Morris EJ, Stefanis L, Troy CM, Shelanski ML, Geller HM, Greene LA. Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J Neurosci 1998; 18: 830–40.[Abstract/Free Full Text]
  107. Zanzinger J. Role of nitric oxide in the neural control of cardiovascular function. Cardiovasc Res 1999; 43: 639–49.[Abstract/Free Full Text]
  108. Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. Am J Clin Nutr 2001; 73: 1052–7.[Abstract/Free Full Text]
  109. Rauch U, Ziegler D, Piolot R, Schwippert B, Benthake H, Schultheiss HP, Tschoepe D. Platelet activation in diabetic cardiovascular autonomic neuropathy. Diabet Med 1999; 16: 848–52.[CrossRef][Medline]
  110. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756–62.[Abstract/Free Full Text]
  111. Goto S, Handa S, Takahashi E, Abe S, Handa M, Ikeda Y. Synergistic effect of epinephrine and shearing on platelet activation. Thromb Res 1996; 84: 351–9.[CrossRef][Medline]
  112. Gawaz M, Brand K, Dickfeld T, Pogatsa-Murray G, Page S, Bogner C, Koch W, Schomig A, Neumann F. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism: implications for atherogenesis. Atherosclerosis 2000; 148: 75–85.[CrossRef][Medline]
  113. Duprez D, De Buyzere M, Rietzschel E, Rimbout S, Kaufman JM, Van Hoecke MJ, Clement DL. Renin-angiotensin-aldosterone system, RR-interval and blood pressure variability during postural changes after myocardial infarction. Eur Heart J 1995; 16: 1050–6.[Abstract/Free Full Text]
  114. Hughson RL, Maillet A, Gauquelin G, Arbeille P, Yamamoto Y, Gharib C. Investigation of hormonal effects during 10-h head-down tilt on heart rate and blood pressure variability. J Appl Physiol 1995; 78: 583–96.[Abstract/Free Full Text]
  115. Binkley PF, Haas GJ, Starling RC, Nunziata E, Hatton PA, Leier CV, Cody RJ. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol 1993; 21: 655–61.[Abstract]
  116. Wenzel RR, Bruck H, Noll G, Schafers RF, Daul AE, Philipp T. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol 2000; 35: S43–52.[Medline]
  117. Campbell WB, Henrich WL. Endothelial factors in the regulation of renin release. Kidney Int 1990; 38: 612–7.[Medline]
  118. Golczynska A, Lenders JW, Goldstein DS. Glucocorticoid-induced sympathoinhibition in humans. Clin Pharmacol Ther 1995; 58: 90–8.[CrossRef][Medline]
  119. Hatakeyama H, Inaba S, Taniguchi N, Miyamori I. Functional adrenocorticotropic hormone receptor in cultured human vascular endothelial cells: possible role in control of blood pressure. Hypertension 2000; 36: 862–5.[Abstract/Free Full Text]
  120. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1992; 89: 9991–5.[Abstract/Free Full Text]
  121. Moan A, Nordby G, Rostrup M, Eide I, Kjeldsen SE. Insulin sensitivity, sympathetic activity, and cardiovascular reactivity in young men. Am J Hypertens 1995; 8: 268–75.[CrossRef][Medline]
  122. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96: 4104–13.[Abstract/Free Full Text]
  123. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46: S9–13.
  124. Scherrer U, Sartori C. Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic overactivity and cardiovascular morbidity. Eur J Endocrinol 2000; 142: 315–23.[Abstract]
  125. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994; 24: 471–6.[Abstract]
  126. Toprakci M, Ozmen D, Mutaf I, Turgan N, Parildar Z, Habif S, Guner I, Bayindir O. Age-associated changes in nitric oxide metabolites nitrite and nitrate. Int J Clin Lab Res 2000; 30: 83–5.[CrossRef][Medline]
  127. White M, Courtemanche M, Stewart DJ, Talajic M, Mikes E, Cernacek P, Vantrimpont P, Leclerc D, Bussieres L, Rouleau JL. Age- and gender-related changes in endothelin and catecholamine release, and in autonomic balance in response to head-up tilt. Clin Sci 1997; 93: 309–16.[Medline]



This article has been cited by other articles:


Home page
Psychosom. Med.Home page
D. C. Cooper, M. S. Milic, J. R. Tafur, P. J. Mills, W. A. Bardwell, M. G. Ziegler, and J. E. Dimsdale
Adverse Impact of Mood on Flow-Mediated Dilation
Psychosom Med, February 1, 2010; 72(2): 122 - 127.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
K. L. Lavoie, R. Pelletier, A. Arsenault, J. Dupuis, and S. L. Bacon
Association Between Clinical Depression and Endothelial Function Measured by Forearm Hyperemic Reactivity
Psychosom Med, January 1, 2010; 72(1): 20 - 26.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
F. Iellamo, M. Tesauro, S. Rizza, S. Aquilani, C. Cardillo, M. Iantorno, M. Turriziani, and R. Lauro
Concomitant Impairment in Endothelial Function and Neural Cardiovascular Regulation in Offspring of Type 2 Diabetic Subjects
Hypertension, September 1, 2006; 48(3): 418 - 423.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
M. A. Robbins, M. F. Elias, P. K. Elias, and M. M. Budge
Blood Pressure and Cognitive Function in an African-American and a Caucasian-American Sample: The Maine-Syracuse Study
Psychosom Med, September 1, 2005; 67(5): 707 - 714.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
P. J. Gianaros, K. Salomon, F. Zhou, J. F. Owens, D. Edmundowicz, L. H. Kuller, and K. A. Matthews
A Greater Reduction in High-Frequency Heart Rate Variability to a Psychological Stressor is Associated With Subclinical Coronary and Aortic Calcification in Postmenopausal Women
Psychosom Med, July 1, 2005; 67(4): 553 - 560.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
M. E. Bleil, J. M. McCaffery, M. F. Muldoon, K. Sutton-Tyrrell, and S. B. Manuck
Anger-Related Personality Traits and Carotid Artery Atherosclerosis in Untreated Hypertensive Men
Psychosom Med, September 1, 2004; 66(5): 633 - 639.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harris, K. F.
Right arrow Articles by Matthews, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harris, K. F.
Right arrow Articles by Matthews, K. A.
Related Collections
Right arrow Psychophysiology
Right arrow Stress and Coping
Right arrow Coronary Artery Disease


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS